Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Steroids and unfractionated heparin in critically ill patients with COVID-19 pneumonia
2020-001921-30Phase 3Terminated
- Sponsor
- AOU Policlinico di Modena
- Start
- Jun 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial in coronavirus disease 2019 (COVID-19), coronavirus pneumonia and viral pneumonia comparing Methylprednisolone + unfractionated heparin, Methylprednisolone + enoxaparin and Enoxaparin alone (3 arms). Primary endpoint: All-cause mortality at day 28. Started Jun 2020; status: terminated.
02
Drugs
methylprednisoloneheparinenoxaparin
03
Conditions
coronavirus disease 2019 (COVID-19)coronavirus pneumoniaviral pneumonia
Beyond the preview
Go deeper on 2020-001921-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001921-30.